Minocycline in Huntington's disease: a pilot study.
Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6-month period and underwent assessments every 2 months with laboratory studies, the Abnormal Involuntary Movements Scale, the Unified Huntington's Disease Rating Scale, and the Mini-Mental State Examination. Minocycline was well tolerated during this study period and no serious adverse events were noted.
Thomas
Madhavi
M
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA. thomasmad@ninds.nih.gov
Ashizawa
Tetsuo
T
Jankovic
Joseph
J
D000328:Adult; D000368:Aged; D061945:Caspase Inhibitors; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D010865:Pilot Projects
D061945:Caspase Inhibitors; D004791:Enzyme Inhibitors; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D008911:Minocycline